Gómez-Sifontes, A. , Diaz-Tablero, J. and Rodriguez, Y. (2025) Anti-C1q Antibodies as Markers of Renal Involvement in Patients with Systemic Lupus Erythematosus, Bolivar City, Venezuela. Open Access ...

A biotech company developing precision therapeutics that selectively eliminate pathogenic antibodies driving autoimmune and ...

Financing of Merida Biosciences was backed by Bain Capital Life Sciences, BVF Partners and Third Rock Ventures, with participation from multiple other investors.

BOSTON — Adults recently diagnosed with immunoglobulin A nephropathy who were assigned sparsentan as first-line therapy experienced rapid and sustained reductions in proteinuria, according to ...

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...

Following its lead Graves’ disease programme, Merida plans to pursue candidates for food allergies and primary membranous nephropathy, a rare autoimmune kidney disorder. Merida will be led by CEO Adam ...

Therefore, I will focus on the most common causes of nephrotic syndrome — minimal change disease, focal segmental glomerulosclerosis (FSGS), and membranous nephropathy. Minimal Change Disease ...

Other disclosed Merida programs are in preclinical development for primary membranous nephropathy, which is a chronic inflammatory kidney disease, and food allergies mediated by immunoglobulin E ...

Merida is working on a selective therapy for Graves’ disease, leveraging targeted therapies that can deplete disease-causing autoantibodies.

Merida is also working on a treatment for a chronic inflammatory kidney disease called primary membranous nephropathy. “At the heart of Merida is understanding the mechanisms behind antibody ...